FORM 4

obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  DAVIS STEPHEN  (Last) (First) (Middle)  C/O ACADIA PHARMACEUTICALS INC.  12830 EL CAMINO REAL, SUITE 400  (Street)  SAN DIEGO CA 92130						2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD  3. Date of Earliest Transaction (Month/Day/Year) 01/06/2022  4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ir	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner  X Officer (give title Other (specify below)  CEO  6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
(City)			(Zip)													Form f Persor	filed by More	e than	One Repo	ting
		Tab	le I - Nor	า-Deriv	ative	Sec	curiti	ies Ac	quire	d, Di	isp	osed c	of, or I	3ene	eficial	ly Owne	d			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ur) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.							Benefic	es ially Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Cod	e v		Amount	(A (D	or	Price	Transac	action(s) 3 and 4)			(111501.4)
Common Stock				01/06	5/2022				М			9,527	7 A		(1)	62,	434 <sup>(2)</sup>	D		
Common	Common Stock 01/06/2				2022		S <sup>(3</sup>			3,718	8 D \$		\$23.0	05 58,716		D				
		Т	able II -	Deriva (e.g., p												Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (I 8)		n of		6. Date Exercisa Expiration Date (Month/Day/Yea		ate		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	able	Ex <sub>I</sub>	piration te	Title	O N O	umber	ber				
Restricted Stock Units	(1)	01/06/2022			М			9,527	(4)			(4)	Commo		9,527	\$0.00	19,056		D	

## **Explanation of Responses:**

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ common \ stock.$
- 2. Includes 1 share of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program.
- 3. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- $4. \ The \ restricted \ stock \ units \ vest \ in \ four \ equal \ annual \ installments \ beginning \ January \ 6, \ 2021.$

## Remarks:

/s/ Austin D. Kim, Attorney-in-Fact

\*\* Signature of Reporting Person

01/10/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.